Pregnancy With Morquio Syndrome - What Are Patients' Perspectives and Has ERT Changed Them?
Status: | Recruiting |
---|---|
Conditions: | Orthopedic, Metabolic, Metabolic |
Therapuetic Areas: | Pharmacology / Toxicology, Orthopedics / Podiatry |
Healthy: | No |
Age Range: | 15 - 100 |
Updated: | 1/26/2019 |
Start Date: | May 10, 2017 |
End Date: | December 2019 |
Contact: | Nadia Ali, Ph.D. |
Email: | Nadia.Ali@emory.edu |
Phone: | 404-778-8613 |
The present study seeks to interview women with Morquio A and Morquio B syndrome, to explore
their concerns surrounding pregnancy and the impact of ERT on their perspectives, in
comparison with the control group of Morquio B subjects for whom no ERT treatment exists.
Interviews will be conducted by a health psychologist, in-person or over the telephone. Data
will be analyzed using MAXQDA 12.0 software and Grounded Theory. Differences in thematic
trends between Morquio A subjects, for whom treatment exists, and a control group of Morquio
B subjects, for whom there is no treatment, will be compared.
their concerns surrounding pregnancy and the impact of ERT on their perspectives, in
comparison with the control group of Morquio B subjects for whom no ERT treatment exists.
Interviews will be conducted by a health psychologist, in-person or over the telephone. Data
will be analyzed using MAXQDA 12.0 software and Grounded Theory. Differences in thematic
trends between Morquio A subjects, for whom treatment exists, and a control group of Morquio
B subjects, for whom there is no treatment, will be compared.
The present study seeks to interview women with Morquio A and Morquio B syndrome themselves,
to explore and discover their perspectives and concerns surrounding pregnancy and having
biological children, the impact of the advent of ERT for Morquio A on their perspectives and
concerns in comparison with the control group of Morquio B subjects for whom no ERT treatment
exists, as well as what each group is being told by the medical community and others in their
lives in this regard.
Interviews will be conducted by a health psychologist, either in-person or over the
telephone. We will interview 1) those women with Morquio syndrome who are known to have been
pregnant and 2) those women with Morquio syndrome who have not been pregnant and/or chose to
adopt children. All information will be kept confidential, except as in accordance with
Georgia law relating to reporting of child or elder abuse, suicidal and/or homicidal intent.
Data will be analyzed using MAXQDA 12.0 software to develop code which can be used to
describe and compare the data using Grounded Theory. Differences in thematic trends between
Morquio A subjects, for whom treatment exists, and a control group of Morquio B subjects, for
whom there is no treatment, will be compared.
to explore and discover their perspectives and concerns surrounding pregnancy and having
biological children, the impact of the advent of ERT for Morquio A on their perspectives and
concerns in comparison with the control group of Morquio B subjects for whom no ERT treatment
exists, as well as what each group is being told by the medical community and others in their
lives in this regard.
Interviews will be conducted by a health psychologist, either in-person or over the
telephone. We will interview 1) those women with Morquio syndrome who are known to have been
pregnant and 2) those women with Morquio syndrome who have not been pregnant and/or chose to
adopt children. All information will be kept confidential, except as in accordance with
Georgia law relating to reporting of child or elder abuse, suicidal and/or homicidal intent.
Data will be analyzed using MAXQDA 12.0 software to develop code which can be used to
describe and compare the data using Grounded Theory. Differences in thematic trends between
Morquio A subjects, for whom treatment exists, and a control group of Morquio B subjects, for
whom there is no treatment, will be compared.
Inclusion Criteria:
1. Documented clinical diagnosis of either MPS IVA or MPS IVB, based on clinical signs
and symptoms, documented reduced fibroblast or leukocyte GALNS enzyme activity or
genetic testing confirming diagnosis.
2. Subject is at least 15 years old.
3. Subject is female.
4. Subject is fluent enough in English to complete in-depth interview with PI.
Exclusion Criteria:
1. Patient has a clinically significant disease other than Morquio which would confound
the effects of Morquio upon study variables.
2. Any condition that, in the view of the Investigator, places the patient at high risk
of poor compliance or of not completing the study.
We found this trial at
1
site
Decatur, Georgia 30033
Principal Investigator: Nadia Ali, Ph.D.
Phone: 404-778-8613
Click here to add this to my saved trials